Common oral medications used to treat diabetes mellitus.
Many studies have suggested that diabetes is a risk factor for the development of cancer, but whether or not cancer itself can increase the risk of diabetes requires further investigation.
Women with type 2 diabetes have a 1.5-fold higher risk of renal cell carcinoma compared with non-diabetic women.
Insulin Pen Devices comparison chart for patients with diabetes mellitus.
It was unknown whether breast cancer treatment plays a causal role in the onset of diabetes.
Of 14,067,894 reported cancer cases in 2012, 280,100 (2%) were attributed to diabetes alone, 544,300 (3.9%) were attributed to a high BMI alone, and 792,600 (5.6%) were attributed to both.
Previous studies investigating the association of long-acting insulin analogues and increased breast cancer risk have been mixed, and the follow-up periods for these studies have been too short to lead to definitive conclusions.
Diabetes is associated with increased mortality from cardiovascular disease, cancer, and noncardiovascular noncancer causes.
Age and history of diabetes may independently be predictors for the development of chemotherapy-induced peripheral neuropathy.
Metformin, traditionally used as a first-line treatment for type 2 diabetes, may be able to reduce a potential source of energy for certain cancer cells.
The use of metformin in standard cancer therapy may improve both overall and cancer-specific survival of patients with diabetes and breast cancer.
Statin use may be associated with a decreased risk of pancreatic cancer in patients with type 2 diabetes.
For patients with diabetes in the U.S., metformin use is associated with reduced risk of developing colorectal cancer (CRC).
Women with diabetes may have an increased risk of being diagnosed with advanced breast cancer.
A large, retrospective cohort study found no evidence that metformin prevents lung cancer, although nonsmokers may find some benefit.
Increased risk of colorectal cancer for diabetes patients with obesity duration of four years or longer.
The protein Sirtuin3 was linked to the development of pulmonary hypertension.
Findings based on large retrospective study of patients with type 2 diabetes.
Findings based on comparison to sulfonylureas and thiazolidinediones.
Para-aortic radiation with ≥36 Gy linked to increased risk of diabetes mellitus.
Changes in adipose tissue precede the development of cachexia symptoms, and suggest a treatment approach.
Retrospective cohort study in Taiwan shows significantly increased risk of cancer.
Metformin doesn't significantly reduce risk of bladder cancer in patients with type 2 diabetes.
In women with type 2 diabetes, thiazolidinediones found particularly protective
An international study that examined short- to mid-term use of various insulins in patients with diabetes found no increased risk of breast cancer.
Increased cumulative duration of metformin after a prostate cancer diagnosis correlates with decreased mortality in elderly men with diabetes.
There is no evidence that patients with diabetes who initiate insulin glargine have a higher risk of cancer than similar patients initiating human neutral protamine Hagedorn insulin.
Drugs designed to treat diabetes may also increase patients' risk for pancreatic cancer.
For more than 50 years, an association between diabetes and an increased risk for cancer has been recognized and supported in numerous studies.
Physician empathy correlates with clinical outcome for patients with diabetes mellitus.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Nivolumab Monotherapy Provides Long Term Benefit Advanced Melanoma
- Risk Score Identifies Adjuvant Chemotherapy Toxicity Risk in Elderly Patients With Breast Cancer
- Despite Breast-Conserving Surgery Eligibility, Nearly 50% of Women Chose Mastectomy
- Lisinopril and Carvedilol May Reduce Cardiotoxicity During Adjuvant Trastuzumab Treatment
- Immune Marker Identified as Prognostic in Triple-Negative Breast Cancer